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Flow cytometric detection of BCR-ABL fusion proteins in leukemia patients via an immunobead assay
INTRODUCTION
The BCR-ABL fusion gene results from the translocation t(9;22).
It is the hallmark of chronic myeloid leukemia (CML) and is present
in a poor-risk subgroup of precursor B cell acute lymphoblastic
leukemia (ALL), which represents 25-30% of adult ALL and 3-5%
of childhood ALL. Consequently the detection of the BCR-ABL
aberration is of utmost importance for diagnosis and classification
of leukemia patients and can also be used as marker for monitoring
+of BCR-ABL  leukemias to evaluate treatment effectiveness.
So far, the BCR-ABL aberration has been detected by cytogenetics,
FISH or PCR, all techniques that are time consuming and require
special facilities.
We developed a simple flow cytometric bead assay for detection of
the BCR-ABL fusion protein in cell lysates, using a bead-bound
catching antibody against one side of the fusion protein and a
fluorochrome-conjugated detection antibody against the other side
of the fusion protein (see Figure 1).
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Figure 2.  Results of the flow cytometric BCR-ABL RUO immunobead assay.
RESULTS
1.  Detection of all variants of the BCR-ABL fusion protein.
The anti-BCR antibody was developed against a non-homologous region of ~80 amino acids, encoded by 
exon 1, which allowed us to detect all known BCR-ABL variants, including p190, p210, and p230, as 
demonstrated by analysis of a series of well-defined cell lines. The assay appeared to be specific and sufficiently 
sensitive to detect BCR-ABL proteins in lysates of leukocyte samples of leukemia patients at diagnosis.
2. Protease inhibition needed in cell samples with many mature myeloid cells. 
Protein stability problems were encountered when cell samples contained high frequencies of mature 
myeloid cells with high levels of protease activity, such as CML cells and granulocyte fractions. This problem 
could be significantly reduced by adding protease inhibitors to several steps of the immunobead assay.
3. Development and testing of standardized Research Use Only (RUO) kit.
The immunobead assay was further developed and standardized by BD Biosciences into the Cytometric Bead 
Array (CBA) assay (BCR-ABL Protein Kit; BD Biosciences, San Jose, CA) for Research Use Only (RUO). The 
BCR-ABL immunobead kit for BCR-ABL fusion protein detection was evaluated in parallel to PCR analysis for 
BCR-ABL transcipt in 9 diagnostic laboratories of the EuroFlow Consortium on a series of 145 freshly collected 
samples from newly diagnosed (n=134) or relapsed (n=11) leukemia patients: 19 CML patients, 78 precursor-
B-ALL patients, 18 T-ALL patients, 27 acute myeloid leukemia (AML) patients, and 3 patients with other 
hematological proliferations (see Table). In addition, 72 healthy controls were tested with the immunobead assay.
4.  High specificity of BCR-ABL immunobead assay.
High concordance (100%; 145/145) was obtained between BCR-ABL PCR results and the BCR-ABL 
immunobead results:
-  17/78 precursor-B-ALL were BCR-ABL positive in both assays (mainly adults)
-  19/19 CML were BCR-ABL positive in both assays (with very weak immunobead signals in one CML case)
-  0/48 of other acute leukemias or proliferations were BCR-ABL positive
5. Two subgroups of pateints according to levels of BCR-ABL expression.
According to the Mean Fluorescence Intensity (MFI) values, two main groups of BCR-ABL positive patient 
samples were seen: high level positivity with MFI values ≥1,000 and low level positivity with MFI values ≥135 
but <1,000. Negative samples were defined as MFI values <135 (see Figure 2). Different MFI values were 
seen in precursor-B-ALL and CML:
     -  Precursor-B-ALL: 88% (15/17) high level positivity
     -  CML: 84% (16/19) low level positivity (true low expression or remaining protease activity?)
CONCLUSIONS
We conclude that the flow cytometric immunobead assay is a fast and easy technique
for specific detection of BCR-ABL proteins in leukemic cells.
1. The main advantages of the immunobead assay are:
     - not dependent of the breakpoint position in the BCR gene;
     - does not need special laboratory facilities other then a routine flow cytometer;
     - provides results within several hours;
     - can be run in parallel to routine immunophenotyping (no extra technician time needed).
2. Since differentially labeled beads allow multiplexing, it will be possible to develop single 
     tube assays for combined evaluation of multiple different fusion proteins, e.g. per disease
     category.
3. Consequently, the flow cytometric immunobead assay can contribute to fast and easy 
     diagnosis and classification of leukemias with fusion genes.
4. If sufficient sensitivity can be reached, also monitoring becomes possible.
* negative: MFI value <135; low positivity: MFI value ≥135 and <1,000; high positivity: ≥1,000
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Figure 1. Principle of the flow cytometric immunobead assay for fusion protein detection.
The target cells are lysed to release the fusion proteins. The bead-bound catching 
antibody recognizes one side of the fusion proteins and the fluorochrome-conjugated
 detection antibody recognizes the other side of the fusion proteins.
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